import{_ as i}from"./dimensions-C4-qSBS3.js";import{V as t}from"./VContainer-CPpRJ5yr.js";import{v as s,x as n,y as o,z as e,az as a}from"./index-CsHsuNZz.js";const r={},c=e("div",null,[e("h2",{class:"text-h4 font-weight-bold pb-5"},"Message from the Foundation Chair"),e("p",null,[a(" Non–small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85-90% of all lung cancer cases. It encompasses several subtypes, the main ones being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Despite their shared classification, each subtype can present distinct histological features and may respond differently to specific treatments."),e("br"),e("br"),a(" Etiology and Risk Factors"),e("br"),a(" • Smoking: Tobacco use is the primary risk factor for NSCLC, although not all patients have a history of smoking (especially those diagnosed with adenocarcinoma)."),e("br"),a(" • Environmental/Occupational Exposures: Chronic inhalation of carcinogens, such as asbestos, radon, and certain chemicals, increases the likelihood of developing NSCLC."),e("br"),a(" • Genetic Predisposition: Mutations in specific genes (e.g., EGFR, ALK, KRAS) can influence the disease’s onset and progression, particularly in certain demographic groups."),e("br"),e("br"),a(" Symptoms and Clinical Presentation"),e("br"),a(" In its early stages, NSCLC may be asymptomatic or present only mild, nonspecific symptoms. As the disease progresses, common signs can include:"),e("br"),a(" • Persistent cough or changes in a chronic cough"),e("br"),a(" • Shortness of breath (dyspnea)"),e("br"),a(" • Chest pain or discomfort"),e("br"),a(" • Unexplained weight loss or loss of appetite"),e("br"),a(" • Hemoptysis (coughing up blood)"),e("br"),e("br"),a(" Diagnosis"),e("br"),a(" To confirm an NSCLC diagnosis, a combination of clinical evaluations and diagnostic tests is typically employed:"),e("br"),a(" 1. Imaging Studies: Chest X-ray or CT scan can reveal suspicious nodules or masses in the lungs."),e("br"),a(" 2. Biopsy: Tissue samples obtained through bronchoscopy, CT-guided needle biopsy, or surgical procedures are essential for histopathological examination, which differentiates NSCLC subtypes."),e("br"),a(" 3. Staging Tests: PET scan, MRI, or additional imaging may be used to determine the cancer’s extent and identify any metastases."),e("br"),e("br"),a(" Treatment Options"),e("br"),a(" Therapeutic strategies for NSCLC depend on the cancer’s stage, molecular profile, and the patient’s overall health. Standard approaches include:"),e("br"),a(" • Surgery: For early-stage NSCLC, surgical resection (lobectomy, pneumonectomy, or segmentectomy) offers the best chance for cure."),e("br"),a(" • Radiation Therapy: Often used either post-surgery (adjuvant) or in patients who are not surgical candidates. Advanced techniques like stereotactic body radiotherapy (SBRT) help target tumors precisely."),e("br"),a(" • Chemotherapy: Platinum-based regimens (e.g., cisplatin or carboplatin combined with another agent) are typically administered, especially for locally advanced or metastatic disease."),e("br"),a(" • Targeted Therapy: Drugs designed to inhibit specific molecular pathways (e.g., EGFR, ALK inhibitors) are highly effective in patients harboring those genetic mutations or alterations."),e("br"),a(" • Immunotherapy: Immune checkpoint inhibitors (such as PD-1 or PD-L1 inhibitors) have significantly improved survival in advanced NSCLC, either alone or in combination with chemotherapy."),e("br"),e("br"),a(" Prognosis and Follow-up"),e("br"),a(" Prognosis varies widely based on stage at diagnosis, molecular markers, and overall patient condition. Early detection usually correlates with better outcomes, especially in patients whose tumors are surgically resectable. Even in advanced stages, newer targeted therapies and immunotherapies offer improved survival and quality of life. Regular follow-up imaging and evaluations are vital to monitor treatment response and detect recurrence or metastasis promptly."),e("br"),e("br"),a(" Ongoing Research"),e("br"),a(" Clinical trials continue to explore novel agents and combination regimens. Particular emphasis is placed on personalized medicine, wherein molecular profiling guides more tailored, effective treatments."),e("br"),e("br"),a(" In summary, NSCLC is a heterogeneous disease with a wide spectrum of pathological and clinical presentations. Evolving diagnostic techniques, coupled with advancements in surgical methods, targeted therapies, and immunotherapies, are steadily improving patient outcomes and offering new hope in the management of this historically challenging cancer. ")])],-1);function l(d,h){return s(),n(t,null,{default:o(()=>[c]),_:1})}const u=i(r,[["render",l]]);export{u as default};
